Compare TRIB & ENVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TRIB | ENVB |
|---|---|---|
| Founded | 1992 | 1994 |
| Country | Ireland | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.4M | 6.7M |
| IPO Year | 1996 | 2000 |
| Metric | TRIB | ENVB |
|---|---|---|
| Price | $6.79 | $1.46 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 13.2K | ★ 54.6K |
| Earning Date | 06-16-2026 | 11-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $39,914,675.00 |
| Revenue This Year | $35.89 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.28 | $1.17 |
| 52 Week High | $14.17 | $795.00 |
| Indicator | TRIB | ENVB |
|---|---|---|
| Relative Strength Index (RSI) | 44.95 | 46.04 |
| Support Level | $6.85 | $1.37 |
| Resistance Level | $7.45 | $1.54 |
| Average True Range (ATR) | 0.88 | 0.10 |
| MACD | 0.04 | -0.00 |
| Stochastic Oscillator | 30.19 | 38.17 |
Trinity Biotech PLC is in the business of developing, manufacturing, and marketing clinical diagnostic products for clinical laboratory and point-of-care sections of the diagnostic market. Its products are used to detect autoimmune, infectious, sexually transmitted diseases, diabetes, and disorders of the liver and intestine. The company also provides raw materials to the life sciences and research industries globally. It markets products under the brand names Recombigen, Unigold, MarBlot, Mardx, Immublot, and others. Geographically, it has three segments, namely the Americas, Asia/Africa, and Europe, from which it derives a majority of its revenue from the Americas segment.
Enveric Biosciences Inc is a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, addiction, and other psychiatric disorders. The company's program, EB-003, is a first-in-class approach to the treatment of difficult-to-address mental health disorders designed to promote neuroplasticity without inducing hallucinations in the patient. The company is also developing EB-002, formerly EB-373, a next-generation synthetic prodrug of the active metabolite, psilocin, which is being studied as a treatment for psychiatric disorders.